Need for immunologic stimulators during immunosuppression produced by major cancer surgery.
Although surgery, radiology, and anticancer chemicals have been effective in the treatment of cancer, the immunologic phase of therapy deserves more effort and thought, because the possibilities are considerable. However, the immunologic phase is so complicated that, without the advances made during the past few years, little could be expected from immunology. The focus of this paper is on the immunosuppression produced by major cancer operations, at which time the patient needs immunologic help.
D000917:Antibody Formation; D001402:B-Lymphocytes / Q000276:immunology; D006801:Humans; D007108:Immune Tolerance; D007111:Immunity, Cellular; D007114:Immunization; D007136:Immunoglobulins / Q000276:immunology; D007165:Immunosuppression Therapy / Q000009:adverse effects; D007166:Immunosuppressive Agents / Q000009:adverse effects; D007167:Immunotherapy; D007694:Killer Cells, Natural / Q000276:immunology; D008222:Lymphokines / Q000276:immunology; D008264:Macrophages / Q000276:immunology; D009369:Neoplasms / Q000276:immunology / Q000601:surgery* / Q000628:therapy; D010586:Phagocytes / Q000276:immunology; D011183:Postoperative Complications / Q000628:therapy*; D013312:Stress, Physiological / Q000276:immunology; D013601:T-Lymphocytes / Q000276:immunology
D007136:Immunoglobulins; D007166:Immunosuppressive Agents; D008222:Lymphokines